Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 25, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Nasopharyngeal CarcinomaNasopharyngeal Cancer

Interventions

DRUG

Fluzoparib and Camrelizumab

Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.

Trial Locations (1)

RECRUITING

Fudan Universtiy Shanghai Cancer Centre, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER